Baseline characteristics of lymphoma patients reported to the CIBMTR from 2008 to 2013
| Variable . | Haploidentical . | URD without ATG . | URD with ATG . | P . |
|---|---|---|---|---|
| No. of patients | 185 | 491 | 241 | |
| No. of centers | 23 | 70 | 48 | |
| Median age at HCT (range), y | 55 (18-75) | 55 (19-74) | 55 (20-73) | .13 |
| Male sex | 118 (64) | 301 (61) | 163 (68) | .25 |
| Race | <.001 | |||
| Caucasian/white | 149 (81) | 469 (96) | 227 (94) | |
| Black | 28 (15) | 4 (<1) | 4 (2) | |
| Others* | 6 (3) | 8 (2) | 2 (<1) | |
| Missing | 2 (1) | 10 (2) | 8 (3) | |
| KPS ≥90 | 145 (78) | 311 (63) | 153 (63) | <.001 |
| HCT–comorbidity index | .001 | |||
| 0 | 79 (43) | 184 (37) | 65 (27) | |
| 1-2 | 51 (28) | 114 (23) | 77 (32) | |
| 3 or more | 55 (30) | 175 (36) | 88 (37) | |
| Missing | 0 | 18 (4) | 11 (5) | |
| Histology | <.001 | |||
| FL | 28 (15) | 130 (26) | 44 (18) | |
| DLBCL | 66 (36) | 94 (19) | 61 (25) | |
| Mantle cell lymphoma | 21 (11) | 83 (17) | 36 (15) | |
| Mature T- and NK-cell lymphomas† | 24 (13) | 79 (16) | 52 (22) | |
| Hodgkin lymphoma | 46 (25) | 105 (21) | 48 (20) | |
| Median interval from diagnosis to HCT (range), mo | 31 (<1-255) | 34 (<1-342) | 32 (4-460) | .19 |
| Remission status at HCT‡ | .02 | |||
| CR | 72 (39) | 215 (44) | 100 (41) | |
| PR | 99 (54) | 215 (44) | 96 (40) | |
| Chemorefractory | 10 (5) | 55 (11) | 40 (17) | |
| Untreated | 2 (1) | 3 (<1) | 3 (1) | |
| Unknown | 2 (1) | 3 (<1) | 2 (< 1) | |
| Disease risk index at HCT | <.001 | |||
| Low | 45 (24) | 199 (41) | 75 (31) | |
| Intermediate | 126 (68) | 263 (49) | 129 (54) | |
| High | 13 (7) | 48 (10) | 37 (15) | |
| Missing | 1 (<1) | 1 (<1) | 0 | |
| History of prior autologous HCT | 72 (39) | 254 (52) | 127 (53) | .006 |
| Conditioning regimen | <.001 | |||
| Flu/Bu ± rituximab | 0 | 130 | 136 | |
| Flu/Cy ± rituximab | 0 | 91 | 19 | |
| Flu/Cy/2 Gy TBI | 185 | 0 | 0 | |
| Flu/Mel ± rituximab | 0 | 153 | 83 | |
| Flu/2Gy TBI ± rituximab | 0 | 117 | 3 | |
| TBI in conditioning | 185 | 117 (24) | 3 (<1) | <.001 |
| Graft type | <.001 | |||
| BM | 172 (93) | 31 (6) | 26 (9) | |
| PB | 13 (7) | 460 (94) | 279 (91) | |
| Male donor to male recipient | 66 (36) | 227 (46) | 124 (51) | <.001 |
| Donor/recipient CMV status | .02 | |||
| ± | 40 (22) | 147 (30) | 70 (29) | |
| Other | 142 (76) | 340 (69) | 166 (69) | |
| Missing | 3 (2) | 4 (<1) | 5 (2) | |
| GVHD prophylaxis | <.001 | |||
| Posttransplant Cy§ | 185 (100) | 0 | 0 | |
| CNI + MMF ± others|| | 0 | 161 (33) | 86 (36) | |
| CNI + MTX ± others (except MMF)¶ | 0 | 253 (52) | 143 (59) | |
| CNI ± others (except MMF/MTX)# | 0 | 77 (16) | 12 (5) | |
| Median follow-up of survivors (range), mo | 36 (5-73) | 35 (4-74) | 35 (<1-75) |
| Variable . | Haploidentical . | URD without ATG . | URD with ATG . | P . |
|---|---|---|---|---|
| No. of patients | 185 | 491 | 241 | |
| No. of centers | 23 | 70 | 48 | |
| Median age at HCT (range), y | 55 (18-75) | 55 (19-74) | 55 (20-73) | .13 |
| Male sex | 118 (64) | 301 (61) | 163 (68) | .25 |
| Race | <.001 | |||
| Caucasian/white | 149 (81) | 469 (96) | 227 (94) | |
| Black | 28 (15) | 4 (<1) | 4 (2) | |
| Others* | 6 (3) | 8 (2) | 2 (<1) | |
| Missing | 2 (1) | 10 (2) | 8 (3) | |
| KPS ≥90 | 145 (78) | 311 (63) | 153 (63) | <.001 |
| HCT–comorbidity index | .001 | |||
| 0 | 79 (43) | 184 (37) | 65 (27) | |
| 1-2 | 51 (28) | 114 (23) | 77 (32) | |
| 3 or more | 55 (30) | 175 (36) | 88 (37) | |
| Missing | 0 | 18 (4) | 11 (5) | |
| Histology | <.001 | |||
| FL | 28 (15) | 130 (26) | 44 (18) | |
| DLBCL | 66 (36) | 94 (19) | 61 (25) | |
| Mantle cell lymphoma | 21 (11) | 83 (17) | 36 (15) | |
| Mature T- and NK-cell lymphomas† | 24 (13) | 79 (16) | 52 (22) | |
| Hodgkin lymphoma | 46 (25) | 105 (21) | 48 (20) | |
| Median interval from diagnosis to HCT (range), mo | 31 (<1-255) | 34 (<1-342) | 32 (4-460) | .19 |
| Remission status at HCT‡ | .02 | |||
| CR | 72 (39) | 215 (44) | 100 (41) | |
| PR | 99 (54) | 215 (44) | 96 (40) | |
| Chemorefractory | 10 (5) | 55 (11) | 40 (17) | |
| Untreated | 2 (1) | 3 (<1) | 3 (1) | |
| Unknown | 2 (1) | 3 (<1) | 2 (< 1) | |
| Disease risk index at HCT | <.001 | |||
| Low | 45 (24) | 199 (41) | 75 (31) | |
| Intermediate | 126 (68) | 263 (49) | 129 (54) | |
| High | 13 (7) | 48 (10) | 37 (15) | |
| Missing | 1 (<1) | 1 (<1) | 0 | |
| History of prior autologous HCT | 72 (39) | 254 (52) | 127 (53) | .006 |
| Conditioning regimen | <.001 | |||
| Flu/Bu ± rituximab | 0 | 130 | 136 | |
| Flu/Cy ± rituximab | 0 | 91 | 19 | |
| Flu/Cy/2 Gy TBI | 185 | 0 | 0 | |
| Flu/Mel ± rituximab | 0 | 153 | 83 | |
| Flu/2Gy TBI ± rituximab | 0 | 117 | 3 | |
| TBI in conditioning | 185 | 117 (24) | 3 (<1) | <.001 |
| Graft type | <.001 | |||
| BM | 172 (93) | 31 (6) | 26 (9) | |
| PB | 13 (7) | 460 (94) | 279 (91) | |
| Male donor to male recipient | 66 (36) | 227 (46) | 124 (51) | <.001 |
| Donor/recipient CMV status | .02 | |||
| ± | 40 (22) | 147 (30) | 70 (29) | |
| Other | 142 (76) | 340 (69) | 166 (69) | |
| Missing | 3 (2) | 4 (<1) | 5 (2) | |
| GVHD prophylaxis | <.001 | |||
| Posttransplant Cy§ | 185 (100) | 0 | 0 | |
| CNI + MMF ± others|| | 0 | 161 (33) | 86 (36) | |
| CNI + MTX ± others (except MMF)¶ | 0 | 253 (52) | 143 (59) | |
| CNI ± others (except MMF/MTX)# | 0 | 77 (16) | 12 (5) | |
| Median follow-up of survivors (range), mo | 36 (5-73) | 35 (4-74) | 35 (<1-75) |
Bu, busulfan; CMV, cytomegalovirus; Cy, cyclophosphamide; Flu, fludarabine; Mel, melphalan; MTX, methotrexate.
Haploidentical: Asian (n = 5), Native American (n = 1); URD: Asian (n = 13), Pacific Islander (n = 2).
Details of mature T-cell and NK-cell neoplasms included in the analysis. For the haploidentical group: PTCL-NOS (peripheral T-cell lymphoma–not otherwise specified) = 7, angioimmunoblastic T-cell lymphoma = 3, extranodal NK/T-cell lymphoma = 5, anaplastic large-cell lymphoma = 3, others = 6. For URD without ATG group: PTCL-NOS = 22, angioimmunoblastic T-cell lymphoma = 11, extranodal NK/T-cell lymphoma = 17, anaplastic large-cell lymphoma = 15, others = 14. For URD with ATG group: PTCL-NOS = 19, angioimmunoblastic T-cell lymphoma = 12, extranodal NK/T-cell lymphoma = 1, anaplastic large-cell lymphoma = 10, others = 10.
The haploidentical HCT, URD without ATG, and URD with ATG groups included 25, 67, and 27 patients, respectively, in CR1 or PR1 at the time of transplantation (P = .66).
Tacrolimus/MMF/Cy (n = 175), cyclosporine/MMF/Cy (n = 1), Cy alone (n = 3), tacrolimus/Cy (n = 4), tacrolimus/MTX/Cy (n = 1), MMF/Cy (n = 1).
CNI/MMF alone (n = 196), CNI/MMF/sirolimus (n = 13), CNI/MMF/MTX (n = 37), CNI/MMF/corticosteroids (n = 1).
CNI/MTX/corticosteroids (n = 3), CNI/MTX alone (n = 315), CNI/MTX/sirolimus (n = 78).
CNI/corticosteroids (n = 1), CNI alone (n = 12), CNI/sirolimus (n = 76).